Amyris Biotechnologies creates renewable products, focusing on fuels and chemicals. The company plans to enter the market by 2011.
The company is developing renewable fuels that reduce lifecycle (GHG) emissions 80%. The fuel source is special in that it is compatible with current gasoline engines, and can be distributed with existing petroleum infrastructure.
Amyris is also developing semi-synthetic artemisinin, a key ingredient in first-line malaria treatments, in hopes of creating a complementary source of non-seasonal, high-quality, affordable artemisinin. This source would supplement the current botanical supply, offering millions of people infected with malaria the chance to gain consistent and reliable access to lower-cost, life-saving Artemisinin-based Combination Therapies (ACTs).
Lastly, Amyris produces environmentally friendly chemicals for a variety of consumer products and industrial applications currently dependent on petrochemical components.
Funding Rounds (12) - $446.89MUpdate
|Date||Amount / Round||Valuation||Lead Investor||Investors|
|Oct, 2016||$5M / Post Ipo Equity||—||—||0|
|Oct, 2016||$25M / Post Ipo Debt||—||—||0|
|Feb, 2012||$83.7M / Post Ipo Equity||—||—||4|
|Oct, 2011||$7M / Post Ipo Equity||—||—||0|
|Oct, 2010||$13.78M / Post Ipo Equity||—||—||0|
|Jun, 2010||$133M / Series D||—||Temasek Holdings||5|
|Dec, 2009||$24.3M / Grant||—||—||0|
|Oct, 2009||$41.75M / Series C||—||—||4|
|Aug, 2008||$21M / Series B||—||—||4|
|Feb, 2008||$2.36M / Venture||—||—||0|
|Sep, 2007||$70M / Series B||—||DAG Ventures||4|
|Oct, 2006||$20M / Series A||—||Khosla Ventures||3|
Current Team (11)Update
|Oct 4, 2016||synbiobeta.com - Amyris Expands in Global Nutraceuticals Market with New Collaboration and Partner Funding of $30 Million|
|Dec 9, 2015||AgFunder News - Ripple Foods Raises $14m Series A to Launch Plant-Based Milk Product in Early 2016 – exclusive|
|Jan 12, 2015||amyris.com - Blog - Amyris|
|Dec 10, 2014||Xconomy - "Innovation at Biotech's Epicenter," Dec. 17: Check Out the Agenda|
|Dec 2, 2014||Xconomy - "Innovation at Biotech's Epicenter," Dec. 17: Check Out the Agenda|
|Nov 20, 2014||Xconomy - Bay Area Innovators To Shake Up "Biotech's Epicenter" Event 12/17|
|Feb 17, 2014||SEC - SEC FORM D|
|Jan 31, 2014||SEC - SEC FORM D|
5885 Hollis Street,
Emeryville, CA 94608